Vault-13

Venrock Adviser, LLC

NEW YORK, NY · CIK 1615982 · 13F filing filed 2025-11-14

SEC-registered investment adviser since 2014 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 11
Palo Alto, CAUnited States United States

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$1.8bn reported value +33.1% vs Q2 2025
33positions
69.0%in top 10
2 new 6 added 6 reduced 0 sold out vs Q2 2025

Holdings, Q3 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 APOGEE THERAPEUTICS INC COM COM 8,493,321 $337.4m18.99% 18.99% UnchangedShares held: Q4 2024 8.5m, Q1 2025 8.5m, Q2 2025 8.5m, Q3 2025 8.5m
2 METSERA INC COM COM 3,750,662 $196.3m11.05% 11.05% UnchangedShares held: Q4 2024 0, Q1 2025 3.8m, Q2 2025 3.8m, Q3 2025 3.8m
3 OCULAR THERAPEUTIX INC COM OCUL OCUL 13,161,462 $153.9m8.66% 8.66% AddedShares held: Q4 2024 12.8m, Q1 2025 12.8m, Q2 2025 12.8m, Q3 2025 13.2m +399.0k +399,000 3.1%
4 CIDARA THERAPEUTICS INC COM NEW CDTX CDTX 946,788 $90.7m5.10% 5.10% AddedShares held: Q4 2024 765.7k, Q1 2025 1.1m, Q2 2025 639.1k, Q3 2025 946.8k +307.7k +307,700 48.1%
5 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 3,882,709 $83.8m4.72% 4.72% UnchangedShares held: Q4 2024 3.9m, Q1 2025 3.9m, Q2 2025 3.9m, Q3 2025 3.9m
6 KALVISTA PHARMACEUTICALS INC COM KALV KALV 6,728,985 $82.0m4.61% 4.61% UnchangedShares held: Q4 2024 6.2m, Q1 2025 6.7m, Q2 2025 6.7m, Q3 2025 6.7m
7 ORUKA THERAPEUTICS INC COM ORKA ORKA 4,148,428 $79.8m4.49% 4.49% UnchangedShares held: Q4 2024 3.3m, Q1 2025 4.1m, Q2 2025 4.1m, Q3 2025 4.1m
8 ORIC PHARMACEUTICALS INC COM ORIC ORIC 6,596,885 $79.2m4.46% 4.46% UnchangedShares held: Q4 2024 4.4m, Q1 2025 3.2m, Q2 2025 6.6m, Q3 2025 6.6m
9 ENLIVEN THERAPEUTICS INC COM ELVN ELVN 3,226,331 $66.0m3.72% 3.72% ReducedShares held: Q4 2024 4.0m, Q1 2025 4.0m, Q2 2025 4.0m, Q3 2025 3.2m -800.0k -800,000 -19.9%
10 COGENT BIOSCIENCES INC COM COGT COGT 4,000,000 $57.4m3.23% 3.23% ReducedShares held: Q4 2024 5.7m, Q1 2025 5.7m, Q2 2025 4.8m, Q3 2025 4.0m -755.4k -755,411 -15.9%
11 CYTOMX THERAPEUTICS INC COM CTMX CTMX 15,561,500 $49.6m2.79% 2.79% AddedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 14.0m, Q3 2025 15.6m +1.6m +1,591,618 11.4%
12 ABIVAX SA SPONSORED ADS ABVX ABVX 576,729 $49.0m2.76% 2.76% ReducedShares held: Q4 2024 1.3m, Q1 2025 1.3m, Q2 2025 1.3m, Q3 2025 576.7k -769.1k -769,051 -57.1%
13 SAVARA INC COM SVRA SVRA 12,681,043 $45.3m2.55% 2.55% AddedShares held: Q4 2024 0, Q1 2025 3.3m, Q2 2025 8.9m, Q3 2025 12.7m +3.8m +3,796,780 42.7%
14 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 2,685,448 $45.0m2.53% 2.53% UnchangedShares held: Q4 2024 2.7m, Q1 2025 2.7m, Q2 2025 2.7m, Q3 2025 2.7m
15 ERASCA INC COM ERAS ERAS 17,857,083 $38.9m2.19% 2.19% UnchangedShares held: Q4 2024 16.2m, Q1 2025 16.2m, Q2 2025 17.9m, Q3 2025 17.9m
16 DIANTHUS THERAPEUTICS INC COM DNTH DNTH 960,803 $37.8m2.13% 2.13% ReducedShares held: Q4 2024 1.7m, Q1 2025 1.7m, Q2 2025 1.0m, Q3 2025 960.8k -39.2k -39,197 -3.9%
17 ENGENE HOLDINGS INC COM COM 5,046,414 $34.5m1.94% 1.94% UnchangedShares held: Q4 2024 5.0m, Q1 2025 5.0m, Q2 2025 5.0m, Q3 2025 5.0m
18 MAZE THERAPEUTICS INC COM MAZE MAZE 1,230,769 $31.9m1.80% 1.80% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 1.2m
19 JADE BIOSCIENCES INC COM NEW JBIO JBIO 3,220,364 $27.8m1.56% 1.56% UnchangedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 3.2m, Q3 2025 3.2m
20 DYNE THERAPEUTICS INC COM DYN DYN 2,173,913 $27.5m1.55% 1.55% UnchangedShares held: Q4 2024 2.2m, Q1 2025 2.2m, Q2 2025 2.2m, Q3 2025 2.2m
21 VOR BIOPHARMA INC COM NEW VOR VOR 499,966 $24.4m1.37% 1.37% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 500.0k
22 UPSTREAM BIO INC COM UPB UPB 1,169,298 $22.0m1.24% 1.24% ReducedShares held: Q4 2024 2.3m, Q1 2025 2.3m, Q2 2025 2.3m, Q3 2025 1.2m -1.1m -1,126,021 -49.1%
23 ZURA BIO LTD CLASS A ORD SHS ZURA ZURA 4,631,216 $20.1m1.13% 1.13% UnchangedShares held: Q4 2024 2.0m, Q1 2025 5.0m, Q2 2025 4.6m, Q3 2025 4.6m
24 ASTRIA THERAPEUTICS INC COM CATB CATB 2,457,348 $17.9m1.01% 1.01% UnchangedShares held: Q4 2024 2.5m, Q1 2025 2.5m, Q2 2025 2.5m, Q3 2025 2.5m
25 PHARVARIS N V COM PHVS PHVS 674,599 $16.8m0.95% 0.95% ReducedShares held: Q4 2024 3.2m, Q1 2025 3.1m, Q2 2025 2.0m, Q3 2025 674.6k -1.4m -1,373,021 -67.0%
26 CRESCENT BIOPHARMA INC. COM CBIO CBIO 1,387,864 $16.5m0.93% 0.93% UnchangedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 1.4m, Q3 2025 1.4m
27 SEPTERNA INC COM SEPN SEPN 610,808 $11.5m0.65% 0.65% AddedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 540.5k, Q3 2025 610.8k +70.4k +70,355 13.0%
28 CULLINAN THERAPEUTICS INC COM CGEM CGEM 1,379,965 $8.2m0.46% 0.46% UnchangedShares held: Q4 2024 1.4m, Q1 2025 1.4m, Q2 2025 1.4m, Q3 2025 1.4m
29 SURROZEN INC COM NEW SRZN SRZN 632,931 $8.2m0.46% 0.46% UnchangedShares held: Q4 2024 0, Q1 2025 632.9k, Q2 2025 632.9k, Q3 2025 632.9k
30 PERCEPTIVE CAP SOLUTIONS COR CL A ORD SHS FRNM FRNM 750,000 $8.0m0.45% 0.45% UnchangedShares held: Q4 2024 750.0k, Q1 2025 750.0k, Q2 2025 750.0k, Q3 2025 750.0k
31 ARTIVA BIOTHERAPEUTICS INC COM ARTV ARTV 1,609,569 $4.6m0.26% 0.26% UnchangedShares held: Q4 2024 1.6m, Q1 2025 1.6m, Q2 2025 1.6m, Q3 2025 1.6m
32 TENAX THERAPEUTICS INC COM NEW TENX TENX 437,708 $3.3m0.19% 0.19% AddedShares held: Q4 2024 208.3k, Q1 2025 208.3k, Q2 2025 98.6k, Q3 2025 437.7k +339.1k +339,144 344.1%
33 CASI PHARMACEUTICALS INC ORD SHS CASIF CASIF 987,259 $1.6m0.09% 0.09% UnchangedShares held: Q4 2024 987.3k, Q1 2025 987.3k, Q2 2025 987.3k, Q3 2025 987.3k